Skip to main content

What are the symptoms of Severe Acute Respiratory Syndrome ( #SARS ) ?

 The incubation period of SARS is usually 2-7 days but may be as long as 10 days.

The first symptom of the illness is generally fever (>38°C), which is often high, and sometimes associated with chills and rigors. It may also be accompanied by other symptoms including headache, malaise, and muscle pain. At the onset of illness, some cases have mild respiratory symptoms. Typically, rash and neurologic or gastrointestinal findings are absent, although a few patients have reported diarrhoea during the early febrile stage.

After 3-7 days, a lower respiratory phase begins with the onset of a dry, non-productive cough or dyspnoea (shortness of breath) that may be accompanied by, or progress to, hypoxemia (low blood oxygen levels). In 10–20% of cases, the respiratory illness is severe enough to require intubation and mechanical ventilation. Chest radiographs may be normal throughout the course of illness, though not for all patients. The white blood cell count is often decreased early in the disease, and many people have low platelet counts at the peak of the disease. 

Source: World Heath Organisation


 


Share this trusted information.

Comments

Popular posts from this blog

#COVID-19 #Vaccines and #Vaccination

  Key Points Available evidence suggests the currently authorized mRNA COVID-19 vaccines (Pfizer-BioNTech and Moderna) provide protection against a variety of strains, including B.1.1.7 (originally identified in the United Kingdom) and B.1.351 (originally identified in South Africa). Other vaccines show reduced efficacy against B.1.351 but may still protect against severe disease. Continued monitoring of vaccine effectiveness against variants is needed. A growing body of evidence indicates that people fully vaccinated with an mRNA vaccine (Pfizer-BioNTech and Moderna) are less likely to have asymptomatic infection or to transmit SARS-CoV-2 to others. Studies are underway to learn more about the benefits of Johnson & Johnson/Janssen vaccine. However, the risk for SARS-CoV-2 infection in fully vaccinated people cannot be completely eliminated as long as there is continued community transmission of the virus. At this time, there are limited data on vaccine effectiveness in people who

Frequently Asked Questions about #COVID-19 #Vaccination

If I have already had COVID-19 and recovered, do I still need to get vaccinated with a COVID-19 vaccine? Yes, you should be vaccinated regardless of whether you already had COVID-19. That’s because experts do not yet know how long you are protected from getting sick again after recovering from COVID-19. Even if you have already recovered from COVID-19, it is possible—although rare—that you could be infected with the virus that causes COVID-19 again. Studies have shown that vaccination provides a strong boost in protection in people who have recovered from COVID-19. Learn more about why getting vaccinated is a safer way to build protection than getting infected. If you were treated for COVID-19 with monoclonal antibodies or convalescent plasma, you should wait 90 days before getting a COVID-19 vaccine. Talk to your doctor if you are unsure what treatments you received or if you have more questions about getting a COVID-19 vaccine. If you or your child has a history of multisystem inflam

COVID 19 - Delta and Delta Plus Variant

SARS-CoV-2 Delta variant, also known as lineage B.1.617.2, is a variant of lineage B.1.617 of SARS-CoV-2, the virus that causes COVID-19. It was first detected in India in late 2020. The World Health Organization (WHO) named it the Delta variant on 31 May 2021. It has mutations in the gene encoding the SARS-CoV-2 spike protein causing the substitutions T478K, P681R and L452R, which are known to affect the transmissibility of the virus as well as whether it can be neutralised by antibodies for previously circulating variants of the COVID-19 virus. Public Health England (PHE) in May 2021 observed secondary attack rates to be 51–67% higher than the alpha variant. On 7 May 2021, PHE changed their classification of lineage B.1.617.2 from a variant under investigation (VUI) to a variant of concern (VOC) based on an assessment of transmissibility being at least equivalent to B.1.1.7 (Alpha variant); the UK's SAGE subsequently estimated a "realistic" possibility of being 50% mor